Kalorama report suggests that pharmacists may soon be prescribing drugs
NEW YORK According to Prescribing Pharmacists: An Emerging Decision Maker, a new report from Kalorama Information, six states may soon be giving pharmacists the authority to independently prescribe prescription drugs.
This could move drug revenues influenced by pharmacists from $77 billion in 2006 to $145 billion by 2012. The study shows that 77 percent of drug purchase decisions are currently made without the influence of a pharmacist, however, by 2012 that percentage will drop to 63 percent.
Florida already allows pharmacists to prescribe independently from an approved list of drugs, and some federal agencies allow pharmacists to prescribe under regulated conditions.
Melissa Elder, the report’s author, said that, “Certainly safety will continue to impact the decision to allow pharmacists to prescribe, but cost-savings, population shifts and numerous other factors are helping to swing the pendulum toward this expansion of the pharmacist’s role.”
Sandoz completes $10 million expansion of N.C. facility
WILSON, N.C. Sandoz recently completed the major phase of its Wilson, North Carolina expansion when over 50 employees moved into a new 30,000 square foot building.
Over 65 new jobs are expected to be created in Wilson as a result of the $10 million expansion. The positions will be filled by pharmaceutical scientists and analytical chemists and will bring the total of employees at the site to almost 480.
“The new laboratories present an excellent workplace and opportunity for top scientists to help us continue to growth in the U.S.,” said Bernhard Hampl, president and chief executive officer of Sandoz. “The new products developed at the site will be the basis for the future growth of the Wilson site.”
Pfizer, Taisho sign letter of intent over schizophrenia drug candidate
TOKYO and NEW YORK Taisho Pharmaceuticals and Pfizer have concluded on a letter of intent with regard to Taisho’s new drug candidate for schizophrenia, TS-032.
The drug is currently in the pre-clinical stage and the letter of intent relates to a proposed license agreement regarding rights for development and commercialization.
Through the agreement, Taisho will grant exclusive development and commercialization rights outside Japan for the drug to Pfizer. Once the agreement is signed, Taisho will receive an initial payment of $22 million as well as milestone and royalties linked to the development and sales of the drug.